Caris Life Sciences, Inc.
Caris Life Sciences, Inc. (CAI) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cai · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$38.00
Consensus
$28.60
+71.3% upside
Low
$21.00
Median: $30 · Last Close: $16.70
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$28.60
71.3% upside
High Target
$38
127.6%
Low Target
$21
25.8%
Current Price
$16.70
as of today
Based on analyst price targets, the CAI stock price prediction for the next 12 months ranges from $21 to $38. The consensus CAI price forecast of $28.60 implies 71.3% upside from the current price of $16.70.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $17.13 | ↑ 2.56% |
1-day model range: $16.94–$17.31. Peak: $17.31 (+2.56%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CAI · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-08 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-05-08 | BTIG | Maintains | Buy→Buy |
| 2026-05-08 | Citigroup | Maintains | Buy→Buy |
| 2026-04-06 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-03-13 | Canaccord Genuity | Maintains | Hold→Hold |
| 2026-02-27 | BTIG | Maintains | Buy→Buy |
| 2026-02-27 | Baird | Maintains | Outperform→Outperform |
| 2026-02-27 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2025-12-22 | Canaccord Genuity | Maintains | Hold→Hold |
| 2025-08-13 | Guggenheim | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Caris Life Sciences, Inc. (CAI) stock. Of the recent 12 rating actions, 0 were upgrades and 0 were downgrades. 7 analysts currently cover CAI.
Analyst Recommendation Trends
CAI analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1.0B
↓ 28.2% YoY
Revenue Next Year
$1.2B
↑ 19.9% YoY
EPS This Year
$0.13
EPS Next Year
$0.36
↑ 168.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast CAI EPS of $0.13 for the current fiscal year, based on estimates from 8 analysts. The CAI revenue forecast is $1.0B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CAI stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CAI price target is $28.60 (+71.3% upside), with an analyst consensus of Buy.
The CAI short-term stock prediction for tomorrow is $17.13 (+2.56%).
Caris Life Sciences, Inc. trades on NASDAQ under the ticker CAI. The CAI stock outlook for 2027 is broadly positive, supported by a Buy consensus among 86% of covering analysts.
Frequently asked questions
CAI forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month CAI price target is $28.60, with a high forecast of $38.00 and a low of $21.00. The median price target is shown in the chart above when available. This implies +71.3% potential upside from the current price of $16.70.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.